« Return To News

Emerging Company Profile: Effusion Dissolution

Lung Therapeutics, Inc. is developing therapies that prevent or resolve fibrosis to treat orphan lung diseases. Lead product LTI-01 is a formulation of a fibrinolytic enzyme in preclinical development to prevent and clear loculated pleural effusion without resorting to surgery.

by Emily Cukier-Meisner, Senior Writer
BIOCENTURY ON BUSINESS

READ FULL ARTICLE